» Articles » PMID: 31174464

Real-world Treatment Patterns and Patient-reported Outcomes in Episodic and Chronic Migraine in Japan: Analysis of Data from the Adelphi Migraine Disease Specific Programme

Overview
Journal J Headache Pain
Publisher Biomed Central
Date 2019 Jun 9
PMID 31174464
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In Japan, detailed information on the characteristics, disease burden, and treatment patterns of people living with migraine is limited. The aim of this study was to compare clinical characteristics, disease burden, and treatment patterns in people with episodic migraine (EM) or chronic migraine (CM) using real-world data from clinical practice in Japan.

Methods: This was an analysis of data collected in 2014 by the Adelphi Migraine Disease Specific Programme, a cross-sectional survey of physicians and their consulting adult patients in Japan, using physician and patient questionnaires. We report patient demographics, prescribed treatment, work productivity, and quality-of-life data for people with CM (≥15 headache days/month) or EM (not fulfilling CM criteria). In descriptive analyses, continuous and categorical measures were assessed using t-tests and Chi-squared tests, respectively.

Results: Physicians provided data for 977 patients (mean age 44.5 years; 77.2% female; 94.5% with EM, 5.5% with CM). A total of 634/977 (64.9%) invited patients (600 with EM; 34 with CM) also provided data. Acute therapy was currently being prescribed in 93.7% and 100% of patients with EM and CM, respectively (p = 0.069); corresponding percentages for current preventive therapy prescriptions were 40.5% and 68.5% (p < 0.001). According to physicians who provided data, preventive therapy was used at least once by significantly fewer patients with EM than with CM (42.3% vs. 68.5%, respectively; p < 0.001). Among patients who provided physicians with information on issues with their current therapy (acute therapy: n = 668 with EM, n = 38 with CM; preventive therapy: n = 295 with EM, n = 21 with CM), lack of efficacy was the most frequently identified problem (acute therapy: EM 35.3%, CM 39.5% [p = 0.833]; preventive therapy: EM 35.3%, CM 52.4% [p = 0.131]). Moderate-to-severe headache-related disability (Migraine Disability Assessment total score ≥ 11) was reported by significantly fewer patients with EM than with CM (21.0% vs. 60.0%, respectively; p < 0.001) among patients who provided data.

Conclusions: Preventive treatment patterns in people with EM versus CM differ in Japan, with both types of migraine posing notable disease burdens. Our findings demonstrate that more effective migraine therapies are required to reduce the burden of the disease.

Citing Articles

Treatment Patterns, Characteristics, and Probable Acute Medication Overprescription Among Patients With Migraine in Japan: A Retrospective Cross-Sectional and Longitudinal Analysis of Health Insurance Claims Data.

Katsuki M, Matsumori Y, Ichihara T, Yamada Y, Kaneko K, Kobayashi Y Cureus. 2025; 16(12):e75928.

PMID: 39830552 PMC: 11739997. DOI: 10.7759/cureus.75928.


Analysis of Acupoint Selection and Combinations in Acupuncture Treatment of Migraine: A Protocol for Data Mining.

He Y, Wu Y, Li X J Pain Res. 2024; 17:4149-4157.

PMID: 39679427 PMC: 11645895. DOI: 10.2147/JPR.S489296.


Real-world evaluation of health-related quality of life in patients with diffuse large B-cell lymphoma based on a multinational survey.

Johnson P, Bailey A, Ma Q, Milloy N, Butcher J, Sanderson I Front Oncol. 2024; 14:1402992.

PMID: 38978741 PMC: 11228594. DOI: 10.3389/fonc.2024.1402992.


The Assessment of Clinical Characteristics, Treatment Patterns, and Burden of Illness in Patients With Episodic and Chronic Migraine: A Cross-Sectional Study.

Irfan S, Mohammed F, Hameed S, Ravi V, V K, S S Cureus. 2024; 16(4):e59073.

PMID: 38800196 PMC: 11128265. DOI: 10.7759/cureus.59073.


Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective.

Takeshima T, Sakai F, Wang X, Yamato K, Kojima Y, Zhang Y Pharmacoeconomics. 2024; 42(7):811-822.

PMID: 38771521 PMC: 11180151. DOI: 10.1007/s40273-024-01380-0.


References
1.
Reilly M, Zbrozek A, Dukes E . The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993; 4(5):353-65. DOI: 10.2165/00019053-199304050-00006. View

2.
Stewart W, Lipton R, Kolodner K, Liberman J, Sawyer J . Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia. 1999; 19(2):107-14; discussion 74. DOI: 10.1046/j.1468-2982.1999.019002107.x. View

3.
Schrag A, Selai C, Jahanshahi M, Quinn N . The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000; 69(1):67-73. PMC: 1737007. DOI: 10.1136/jnnp.69.1.67. View

4.
Lipton R, Hamelsky S, Kolodner K, Steiner T, Stewart W . Migraine, quality of life, and depression: a population-based case-control study. Neurology. 2000; 55(5):629-35. DOI: 10.1212/wnl.55.5.629. View

5.
Stewart W, Lipton R, Dowson A, Sawyer J . Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001; 56(6 Suppl 1):S20-8. DOI: 10.1212/wnl.56.suppl_1.s20. View